QuantumCore announced the appointment of David Marantz to its board of directors as the company continues advancing its quantum infrastructure and enabling hardware technology strategy for the quantum computing ecosystem.
Marantz is a technology and healthcare executive with more than 15 years of experience scaling high growth companies, raising capital, and leading strategic transformations across healthcare, benefits, and SaaS businesses. He currently serves as chief executive officer and a director of Mednow, where he led the company’s turnaround and take-private process, including a restructuring that secured more than $5 million in new capital, reduced costs, and returned the business to growth.
Before becoming CEO, Marantz served as Mednow’s chief revenue officer, helping scale revenue through organic growth initiatives and acquisitions. During his tenure, the company integrated the Medvisit physician homecare platform and secured partnerships with Medcan, Dexcom, and Co-operators Insurance. Marantz also serves as an advisor to EverKind, an AI-powered mental health startup, supporting commercialization and go-to-market strategy efforts. Earlier in his career, he worked as a large enterprise sales director at League.
Marantz holds both an MBA and HBA from the Richard Ivey School of Business and is involved in volunteer work with Ronald McDonald House and the Toronto Humane Society.
The company also announced that Christopher Wilson has resigned from QuantumCore’s board of directors. Wilson will remain in his position as Chief Technology Officer and is expected to be included in the slate of director nominees for election at the company’s next annual shareholder meeting, subject to board approval.
QuantumCore is focused on developing enabling hardware technologies for the quantum computing ecosystem, including superconducting amplifier platforms and cryogenic signal technologies designed to support scalable quantum computing systems.
